A Randomized Trial of Erythropoietin for Neuroprotection in Preterm Infants
2020; Massachusetts Medical Society; Volume: 382; Issue: 3 Linguagem: Inglês
10.1056/nejmoa1907423
ISSN1533-4406
AutoresSandra E. Juul, Bryan A. Comstock, Rajan Wadhawan, Dennis E. Mayock, Sherry E. Courtney, Tonya Robinson, Kaashif A. Ahmad, Ellen Bendel‐Stenzel, Mariana Baserga, Edmund F. LaGamma, L. Corbin Downey, Raghavendra Rao, Nancy Fahim, Andrea Lampland, Ivan D. Frantz, Janine Y. Khan, Michael Weiss, Maureen Gilmore, Robin K. Ohls, Nishant Srinivasan, Jorge Perez, Victor McKay, Phuong T. Vu, Jean Lowe, Karl Kuban, T. Michael O’Shea, Adam L. Hartman, Patrick J. Heagerty,
Tópico(s)Cerebral Palsy and Movement Disorders
ResumoHigh-dose erythropoietin has been shown to have a neuroprotective effect in preclinical models of neonatal brain injury, and phase 2 trials have suggested possible efficacy; however, the benefits and safety of this therapy in extremely preterm infants have not been established.
Referência(s)